Study of the Characteristics of Chronic Pain in Patients With Addiction (ADDICTALGO)

Descriptive, Prospective Study of the Characteristics of Chronic Pain in Patients With Addiction to at Least One Substance

It is described in the literature a higher prevalence of pain in patients with an addiction but there are few studies describing the pain profile of patients with use disorder.

Pain has a very negative impact on the quality of life of opioid substituted patients. Improving knowledge on this point would make it possible to better guide specific care.

The investigator proposes to conduct a single-center descriptive observational study using questionnaires, without changing the management of patients with chronic pain.

The primary objective of the study is to determine the prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment.

Study Overview

• Status: Recruiting
• Conditions: Chronic Pain; Addiction

Detailed Description

It is described in the literature a higher prevalence of pain in patients with an addiction but there are few studies describing the pain profile of patients with use disorder.

Pain has a very negative impact on the quality of life of opioid substituted patients. Improving knowledge on this point would make it possible to better guide specific care.

The investigator proposes to conduct a single-center descriptive observational study using questionnaires, without changing the management of patients with chronic pain. All patients admitted to hospitalization in the addiction department of the LORIENT Hospital will be offered participation in the study.

The primary objective of the study is to determine the prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment.

The study will also evaluate the impact on daily activities of the presence of two chronic pathologies: chronic pain and addiction, describe the frequency of the two main psychiatric comorbidities of chronic pain: anxiety and depression, describe the different components of chronic pain in patients with substance addiction, and get information on analgesic medications.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Alexandre Cauchie, MD; Phone Number: + 33 2 97 06 72 90; Email: a.cauchie@ghbs.bzh

Study Locations

• France
  • Lorient, France, 56100
    • Recruiting
    • Groupe Hospitalier Bretagne Sud
    • Contact: Alexandre Cauchie, MD; Phone Number: 02 97 06 72 90; Email: a.cauchie@ghbs.bzh

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized in the addictology department of LORIENT Hospital, in full hospitalization or in a day hospital

Description

Inclusion Criteria:

• > 18 years old
• Presence of addiction to at least one substance, based on DSM-5 criteria
• Hospitalized in the addiction service of LORIENT Hospital
• Knowing how to read and write French
• Not objecting to their participation in the study after informed information

Exclusion Criteria:

• Already included during a precedent hospitalization
• Adults subject to legal protection or deprived of their liberty.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment.	Percentage of patients presenting with pain for more than three months among patients hospitalized in an addiction service for the management of an addiction	During the hospitalization, maximum 1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain intensity in the last 24 hours	Results of the Brief Pain Inventory : worst and least of pain in the last 24 hours	During the hospitalization, maximum 1 month
Interference of pain on the quality of life	Result of Brief pain inventory on general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life. On a scale from 0 (does not interfere) to 10 (completely interferes)	During the hospitalization, maximum 1 month
Localisation of pain	Drawing on a diagram of a human body	During the hospitalization, maximum 1 month
Describe the frequency of the two main psychiatric comorbidities of chronic pain: anxiety	Results of the anxiety scale of Hospital Anxiety and Depression scale. Positive if > 8. Minimum 0, maximum 21	During the hospitalization, maximum 1 month
Describe the frequency of the two main psychiatric comorbidities of chronic pain: depression	Results of the depression scale of Hospital Anxiety and Depression scale. Positive if > 8. Minimum 0, maximum 21	During the hospitalization, maximum 1 month
Describe the prevalence of fibromyalgia among patients with substance addiction	Results of the Fibromyalgia Rapid Screening Tool. Suspicion of fibromyalgia if >5 yes. Maximum 6 yes	During the hospitalization, maximum 1 month
Information on analgesics medication	Collection of current analgesic medication taken every day	During the hospitalization, maximum 1 month
Describe the prevalence of neuropathic pain among patients with substance addiction	Results of the DN3 (neuropathic pain 3). Suspicion of neuropathic pain when > 3/7	During the hospitalization, maximum 1 month

Collaborators and Investigators

• Sponsor: Groupe Hospitalier de Bretagne Sud
• Investigators: Principal Investigator: Alexandre Cauchie, MD, GH Bretagne Sud

Publications and helpful links

General Publications

• Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009. Epub 2005 Aug 10.
• Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003 May 14;289(18):2370-8. doi: 10.1001/jama.289.18.2370.
• Larson MJ, Paasche-Orlow M, Cheng DM, Lloyd-Travaglini C, Saitz R, Samet JH. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addiction. 2007 May;102(5):752-60. doi: 10.1111/j.1360-0443.2007.01759.x.
• Lusted A, Roerecke M, Goldner E, Rehm J, Fischer B. Prevalence of pain among nonmedical prescription opioid users in substance use treatment populations: systematic review and meta-analyses. Pain Physician. 2013 Nov-Dec;16(6):E671-84.
• Voon P, Greer AM, Amlani A, Newman C, Burmeister C, Buxton JA. Pain as a risk factor for substance use: a qualitative study of people who use drugs in British Columbia, Canada. Harm Reduct J. 2018 Jul 5;15(1):35. doi: 10.1186/s12954-018-0241-y.

Study record dates

Study Major Dates

• Study Start (Actual): December 10, 2022
• Primary Completion (Estimated): June 10, 2024
• Study Completion (Estimated): October 10, 2024

Study Registration Dates

• First Submitted: July 11, 2023
• First Submitted That Met QC Criteria: July 27, 2023
• First Posted (Actual): August 4, 2023

Study Record Updates

• Last Update Posted (Actual): September 1, 2023
• Last Update Submitted That Met QC Criteria: August 30, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Compulsive Behavior; Impulsive Behavior; Chronic Pain; Behavior, Addictive
• Other Study ID Numbers: 56LORC_2021_ADDICTALGO

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No